India Pharmas Seen Shifting From Infectious Diseases To Long-Term Chronic Ailments (India)
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical companies appear to be shifting their product-development emphasis away from infectious diseases and more toward treating chronic diseases. Cardiovascular and diabetes diseases are now seen as having the highest growth potential in a segment of ailments driven by increasing urbanization and aging populations. The most successful drugs in that category are expected to be those required for the rest of the patient's life. (Click here for more